文献速递呼吸道感染呼吸危重症与机械通气

高滴度抗流感免疫血浆治疗重症甲型流感的随机双盲3期试验

Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2019-09-30

在美国41个中心开展的随机双盲3期试验中,将高滴度抗流感血浆(血凝抑制抗体滴度≥1:80)与低滴度血浆(≤1:10)进行比较,受试者为PCR确诊甲型流感且NEWS评分≥3分的成人与儿童。

要点

  • 高滴度抗流感血浆较非免疫血浆无显著临床获益。
  • 研究因独立疗效分析显示条件效能低而提前终止。

核心结论

  • 高滴度抗流感血浆较非免疫血浆未带来显著获益。
  • 研究精度不足以排除小的临床相关效应,但获益不足以支持用免疫血浆治疗重症甲型流感。

研究设计与样本

  • 随机、双盲、3期试验,在美国41个医疗中心开展。
  • 纳入PCR确诊甲型流感、全国早期预警评分≥3分、发病至随机化6天内的儿童和成人。
  • 按2:1随机分配接受2单位(或儿童等效量)高滴度血浆(n=92)或低滴度血浆(n=48),随访28天。
  • 随机化按严重程度和年龄(<18岁与≥18岁)分层,受试者、中心人员和研究团队均设盲。
  • 主要分析在意向治疗人群中进行,排除2例未接受血浆者。

主要发现

  • 共入组200例(177例成人、23例儿童),140例符合随机化标准。
  • 138例中47例(34%)发生88例次严重不良事件:高滴度组32例(35%)60例次,低滴度组15例(32%)28例次。
  • 常见严重不良事件包括ARDS(4例[4%] vs 2例[4%])、过敏性输血反应(2例[2%] vs 2例[4%])、呼吸窘迫(3例[3%] vs 无)。

关键数值与推荐

  • 高滴度血浆定义:血凝抑制抗体滴度≥1:80;低滴度血浆:≤1:10。
  • 主要终点为第7天六分类序贯量表临床状态,采用比例优势模型分析,OR>1表示高滴度组各分类临床状态改善。
  • 研究于2018年7月终止,因独立疗效分析显示即使达到完全入组(150例)检测高滴度血浆效应的条件效能仍低。

临床怎么用

  • 现有证据不支持将高滴度抗流感免疫血浆用于重症甲型流感患者的治疗。
  • 临床决策仍应以常规抗病毒治疗与支持治疗为主。

局限性

  • 研究提前终止,样本量有限,精度不足以排除小的临床相关效应。
  • 实际随机化140例,未达到计划的150例完全入组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infection with influenza virus causes substantial morbidity and mortality globally, although antiviral treatments are available. Previous studies have suggested that anti-influenza immune plasma could be beneficial as treatment, but they were not designed as randomised, blinded, placebo-controlled trials. Therefore, we aimed to prospectively evaluate the clinical efficacy of high-titre immune plasma compared with standard low-titre plasma to improve outcomes in patients with severe influenza A infection. METHODS: We did this randomised, double-blind, phase 3 trial at 41 US medical centres to assess the efficacy of high-titre anti-influenza plasma (haemagglutination inhibition antibody titre ≥1:80) compared with low-titre plasma (≤1:10). Children and adults with PCR-confirmed influenza A infection, a National Early Warning score of 3 or greater, and onset of illness within 6 days before randomisation were eligible. Patients were randomly assigned (2:1) using an interactive web response system to receive either two units (or paediatric equivalent) of high-titre plasma (high-titre group) or low-titre plasma (low-titre group), and were followed up for 28 days from randomisation. High-titre and low-titre plasma had the same appearance. Randomisation was stratified by severity (in intensive care unit, not in intensive care but requiring supplemental oxygen, or not in intensive care and not requiring supplemental oxygen) and age (<18 years and ≥18 years). All participants, site staff, and the study team were masked to treatment allocation until after the final database lock. The primary endpoint was clinical status assessed by a six-point ordinal scale on day 7 (death, in intensive care, hospitalised but requiring supplemental oxygen, hospitalised not requiring supplemental oxygen, discharged but unable to resume normal activities, and discharged with full resumption of normal activities) analysed in a proportional odds model (an odds ratio [OR] >1 indicates improvement in clinical status across all categories for the high-titre vs the low-titre group). The primary analysis was done in the intention-to-treat population, excluding two participants who did not receive plasma. This trial is registered with ClinicalTrials.gov, NCT02572817. FINDINGS: Participants were recruited between Jan 26, 2016, and April 19, 2018. Of 200 participants enrolled (177 adults and 23 children), 140 met the criteria for randomisation and were assigned to the high-titre group (n=92) or to the control low-titre group (n=48). One participant from each group did not receive plasma. At baseline, 60 (43%) of 138 participants were in intensive care and 55 (71%) of 78 participants who were not in intensive care required oxygen. 93% of planned plasma infusions were completed. The study was terminated in July, 2018, when independent efficacy analysis showed low conditional power to detect an effect of high-titre plasma even if full accrual (150 participants) was achieved. The proportional OR for improved clinical status on day 7 was 1·22 (95% CI 0·65-2·29, p=0·54). 47 (34%) of 138 participants experienced 88 serious adverse events: 32 (35%) with 60 events in the high-titre group and 15 (32%) with 28 events in the low-titre group. The most common serious adverse events were acute respiratory distress syndrome (ARDS; four [4%] vs two [4%]), allergic transfusion reactions (two [2%] vs two [4%]), and respiratory distress (three [3%] vs none). 65 (47%) participants experienced 183 adverse events: 42 (46%) with 126 events in the high-titre group and 23 (49%) with 57 events in the low-titre group. The most common adverse events were anaemia (four [3%] vs two [4%]) and ARDS (four [3%] vs three [5%]). Ten patients died during the study (six [7%] in the high-titre group vs four [9%] in the low-titre group, p=0·73). The most common cause of death was worsening of acute respiratory distress syndrome (two [2%] vs two [4%] patients). INTERPRETATION: High-titre anti-influenza plasma conferred no significant benefit over non-immune plasma. Although our study did not have the precision to rule out a small, clinically relevant effect, the benefit is insufficient to justify the use of immune plasma for treating patients with severe influenza A. FUNDING: National Institute of Allergy and Infectious Diseases of the National Institutes of Health (Bethesda, MD, USA).

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Beigel JH, Aga E, Elie-Turenne MC, et al. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2019. PMID: 31582360. doi:10.1016/S2213-2600(19)30199-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。